Compare ALDX & AUBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALDX | AUBN |
|---|---|---|
| Founded | 2004 | 1907 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.1M | 92.5M |
| IPO Year | 2014 | 1996 |
| Metric | ALDX | AUBN |
|---|---|---|
| Price | $0.92 | $26.36 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 950.4K | 2.0K |
| Earning Date | 11-04-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 4.00% |
| EPS Growth | ★ 40.43 | 13.66 |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $619,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.39 |
| Revenue Growth | N/A | ★ 0.81 |
| 52 Week Low | $1.07 | $21.60 |
| 52 Week High | $5.93 | $28.88 |
| Indicator | ALDX | AUBN |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 54.69 |
| Support Level | N/A | $26.02 |
| Resistance Level | $1.58 | $27.00 |
| Average True Range (ATR) | 0.11 | 0.53 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.00 | 34.09 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.